Imagion Biosystems Limited
Imagion Biosystems Limited
Your view on IBX.AX
Overview
What the company does, where it operates, and who runs it.
About Imagion Biosystems Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Robert Romeo Proulx
- Headquarters
- Suite 2, Melbourne, VIC, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Robert Romeo Proulx
- Headquarters
- Suite 2, Melbourne, VIC, AU
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Imagion Biosystems Limited, and the rating behind it. IBX.AX last traded at AUD 0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Imagion Biosystems Limited. Starting points for Imagion Biosystems Limited: EPS -AUD 0.02, beta -0.21 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Imagion Biosystems Limited. Imagion Biosystems Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Imagion Biosystems Limited. Trailing twelve-month EPS for Imagion Biosystems Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Imagion Biosystems Limited. Imagion Biosystems Limited has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Imagion Biosystems Limited valued side by side against its closest peers. Imagion Biosystems Limited is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Imagion Biosystems Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Imagion Biosystems Limited executives and directors. Shares of Imagion Biosystems Limited have traded between AUD 0.01 and AUD 0.06 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Imagion Biosystems Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Imagion Biosystems Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Imagion Biosystems Limited. Coverage tracks Imagion Biosystems Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.